Physician profile
Robert S Callaghan
NPI 1275520033
$8,096.83
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,262 · 2020: $383 · 2022: $293 · 2023: $2,520 · 2024: $2,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,068 · Education: $91.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,068.19 |
| Education | $91.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $761.55 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $586.05 | 2019-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Supernus Pharmaceuticals, INC. | $575.45 | 2022-2024 | Qelbree, Qelbree |
| Abbvie INC. | $503.74 | 2022-2024 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $496.89 | 2019-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $461.39 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $437.55 | 2023-2024 | Austedo Xr, Uzedy, Austedo |
| Tris Pharma INC | $418.79 | 2019-2024 | Dyanavel Xr |
| Corium, LLC | $353.70 | 2023-2024 | Azstarys |
| Neos Therapeutics, LP | $338.53 | 2019-2024 | Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $332.48 | 2019-2024 | Ingrezza |
| Alkermes, INC. | $324.89 | 2022-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $300.17 | 2023-2024 | Caplyta |
| Shire North American Group INC | $291.24 | 2019 | |
| Axsome Therapeutics, INC. | $284.45 | 2023-2024 | Auvelity |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $275.98 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Almatica Pharma LLC | $208.12 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $204.58 | 2019-2024 | Jornay Pm |
| Bausch Health US, LLC | $176.52 | 2023 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $132.48 | 2019-2024 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $96.09 | 2023 | Quviviq |
| Allergan, INC. | $86.39 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $84.27 | 2019 | |
| Noven Therapeutics, LLC | $83.30 | 2024 | Secuado, Xelstrym |
| Rhodes Pharmaceuticals L.P. | $68.66 | 2019 | |
| Adlon Therapeutics L.P. | $54.04 | 2019-2020 | |
| Owp Pharmaceuticals, INC. | $46.27 | 2019-2020 | |
| Sage Therapeutics, LLC | $46.18 | 2024 | |
| Neuronetics, INC. | $28.60 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.68 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.80 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Callaghan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.